Brixton BiosciencesMay 14, 2024Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain
Brixton BiosciencesOctober 26, 2023BRIXTON BIOSCIENCES’ COOLIO™ THERAPY GRANTED BREAKTHOUGH DEVICE DESIGNATION BY FDA
